Multipal Sclerosis
Medical Cannabis supports a variety of symptoms faced by MS patients such as pain, tremor and spasms. In addition, certain strains can support sleep and promote appetite.
We provide professional counseling for treatment and strains to our patients, in a set meeting with one of our registered nurses in our clinic.
 
The Indication by the Israeli Ministry of Health:
Multiple Sclerosis- Patients suffering from spasticity that aren’t responding to conventional treatment options. 
 
Get a License

Research

Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.

Zajicek JP, Sanders HP, Wight DE, Vickery PJ, Ingram WM, Reilly SM, Nunn AJ, Teare LJ, Fox PJ, Thompson AJ.

J Neurol Neurosurg Psychiatry. 2005 Dec;76(12):1664-9.

Department of Mathematics and Statistics, University of Plymouth, Room N16, ITTC Building, Tamar Science Park, Plymouth, Devon PL6    8BX, UK. john.zajicek@phnt.swest.nhs.uk

These data provide limited evidence for a longer term treatment effect of cannabinoids. A long term placebo controlled study is now needed to establish whether cannabinoids may have a role beyond symptom amelioration in MS.

_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _

Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.

Wade DT, Makela P, Robson P, House H, Bateman C.

Mult Scler. 2004 Aug;10(4):434-41.

Oxford Centre for Enablement, Windmill Road, Oxford OX3 7LD, UK. derick.wade@dsl.pipex.com

_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _

Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis.

Conte A, Bettolo CM, Onesti E, Frasca V, Iacovelli E, Gilio F, Giacomelli E, Gabriele M, Aragona M, Tomassini V, Pantano P, Pozzilli C, Inghilleri MEur J Pain. 2009 May;13(5):472-7.

The study provides objective neurophysiological evidence that cannabinoids modulate the nociceptive system..

_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _

The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis

David Baker, Gareth Pryce, Samuel J. Jackson, Chris Bolton, Gavin Giovannoni

Department of Neuroscience and Trauma, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom


Role of cannabinoids in multiple sclerosis.
 
Zajicek JP, Apostu VI.
Clinical Neurology Research Group, Peninsula College of Medicine and Dentistry, Plymouth, UK. john.zajicek@phnt.swest.nhs.uk.
 
 

 
CANNABIDIOL INHIBITS PATHOGENIC T-CELLS, DECREASES SPINAL MICROGLIAL ACTIVATION AND AMELIORATES MULTIPLE SCLEROSIS-LIKE DISEASE IN C57BL/6 MICE.
 
Kozela E, Lev N, Kaushansky N, Eilam R, Rimmerman N, Levy R, Ben-Nun A, Juknat A, Vogel Z.
The Dr. Miriam and Sheldon G. Adelson Center for the Biology of Addictive Diseases, Physiology and Pharmacology Department, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Neurology Department, Rabin Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Immunology Department, Histology Department, Neurobiology Department, Weizmann Institute of Science, Rehovot, Israel.
 
 
Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.

Zajicek JP, Sanders HP, Wight DE, Vickery PJ, Ingram WM, Reilly SM, Nunn AJ, Teare LJ, Fox PJ, Thompson AJ.

J Neurol Neurosurg Psychiatry. 2005 Dec;76(12):1664-9.

Department of Mathematics and Statistics, University of Plymouth, Room N16, ITTC Building, Tamar Science Park, Plymouth, Devon PL6    8BX, UK. john.zajicek@phnt.swest.nhs.uk

These data provide limited evidence for a longer term treatment effect of cannabinoids. A long term placebo controlled study is now needed to establish whether cannabinoids may have a role beyond symptom amelioration in MS.

_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _

Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.

Wade DT, Makela P, Robson P, House H, Bateman C.

Mult Scler. 2004 Aug;10(4):434-41.

Oxford Centre for Enablement, Windmill Road, Oxford OX3 7LD, UK. derick.wade@dsl.pipex.com

_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _

Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis.

Conte A, Bettolo CM, Onesti E, Frasca V, Iacovelli E, Gilio F, Giacomelli E, Gabriele M, Aragona M, Tomassini V, Pantano P, Pozzilli C, Inghilleri MEur J Pain. 2009 May;13(5):472-7.

The study provides objective neurophysiological evidence that cannabinoids modulate the nociceptive system..

_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _

The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis

David Baker, Gareth Pryce, Samuel J. Jackson, Chris Bolton, Gavin Giovannoni

Department of Neuroscience and Trauma, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom


Role of cannabinoids in multiple sclerosis.
 
Zajicek JP, Apostu VI.
Clinical Neurology Research Group, Peninsula College of Medicine and Dentistry, Plymouth, UK. john.zajicek@phnt.swest.nhs.uk.
 
http://www.ncbi.nlm.nih.gov/pubmed/21323391
 

 
CANNABIDIOL INHIBITS PATHOGENIC T-CELLS, DECREASES SPINAL MICROGLIAL ACTIVATION AND AMELIORATES MULTIPLE SCLEROSIS-LIKE DISEASE IN C57BL/6 MICE.
 
Kozela E, Lev N, Kaushansky N, Eilam R, Rimmerman N, Levy R, Ben-Nun A, Juknat A, Vogel Z.
The Dr. Miriam and Sheldon G. Adelson Center for the Biology of Addictive Diseases, Physiology and Pharmacology Department, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Neurology Department, Rabin Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Immunology Department, Histology Department, Neurobiology Department, Weizmann Institute of Science, Rehovot, Israel.
 
http://www.ncbi.nlm.nih.gov/pubmed/21449980